123 related articles for article (PubMed ID: 37243480)
21. Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.
Alder L; Trapani D; Bradbury C; Van Swearingen AED; Tolaney SM; Khasraw M; Anders CK; Lascola CD; Hsu L; Lin NU; Sammons S
NPJ Breast Cancer; 2023 Mar; 9(1):19. PubMed ID: 36997605
[TBL] [Abstract][Full Text] [Related]
22. Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort.
Ratosa I; Dobnikar N; Bottosso M; Dieci MV; Jacot W; Pouderoux S; Ribnikar D; Sinoquet L; Guarneri V; Znidaric T; Darlix A; Griguolo G
Int J Cancer; 2022 Oct; 151(8):1355-1366. PubMed ID: 35666525
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Role of Ventricular Size and Its Dynamics in Patients With Leptomeningeal Metastasis From Solid Tumors.
Le Rhun E; Devos P; Seystahl K; Jongen JLM; Gramatzki D; Roth P; Van Den Bent MJ; Regli L; Brandsma D; Weller M
Neurology; 2024 Mar; 102(5):e207959. PubMed ID: 38335471
[TBL] [Abstract][Full Text] [Related]
24. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
[TBL] [Abstract][Full Text] [Related]
25. Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM).
Niwińska A; Pogoda K; Michalski W; Kunkiel M; Jagiełło-Gruszfeld A
J Neurooncol; 2018 May; 138(1):191-198. PubMed ID: 29435818
[TBL] [Abstract][Full Text] [Related]
26. Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype.
Kim HK; Lee HS; Heo MH; Kim JY; Ahn JS; Im YH; Lee JI; Park YH
Clin Breast Cancer; 2021 Aug; 21(4):e402-e414. PubMed ID: 33526378
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
28. Prognostic importance of steroid receptor status for disease free and overall survival after surgical resection of isolated liver metastasis in breast cancer patients.
Zegarac M; Nikolic S; Gavrilovic D; Kolarevic D; Jevric M; Nikolic-Tomasevic Z; Kocic M; Djurisic I; Inic Z; Markovic I; Buta M; Ninkovic S; Dzodic R
J BUON; 2017; 22(1):192-199. PubMed ID: 28365954
[TBL] [Abstract][Full Text] [Related]
29. Patient outcomes of whole brain radiotherapy for brain metastases versus leptomeningeal metastases: A retrospective study.
Sakaguchi M; Maebayashi T; Aizawa T; Ishibashi N; Saito T
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e449-e457. PubMed ID: 27620060
[TBL] [Abstract][Full Text] [Related]
30. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure.
Kazda T; Hardie JG; Pafundi DH; Kaufmann TJ; Brinkmann DH; Laack NN
J Neurooncol; 2015 Mar; 122(1):197-203. PubMed ID: 25577400
[TBL] [Abstract][Full Text] [Related]
32. Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases.
Puri A; Mylavarapu C; Xu J; Patel TA; S Teh B; Tremont-Lukats I; Chang JC; Niravath P
Breast Cancer Res Treat; 2022 Jun; 193(3):613-623. PubMed ID: 35460498
[TBL] [Abstract][Full Text] [Related]
33. Comparing available criteria for measuring brain metastasis response to immunotherapy.
Qian JM; Mahajan A; Yu JB; Tsiouris AJ; Goldberg SB; Kluger HM; Chiang VLS
J Neurooncol; 2017 May; 132(3):479-485. PubMed ID: 28275886
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of pseudoprogression in patients with glioblastoma.
Kucharczyk MJ; Parpia S; Whitton A; Greenspoon JN
Neurooncol Pract; 2017 Jun; 4(2):120-134. PubMed ID: 31386017
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Therapy Response to Transarterial Radioembolization for Liver Metastases by Means of Post-treatment MRI-Based Texture Analysis.
Reimer RP; Reimer P; Mahnken AH
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1545-1556. PubMed ID: 29881933
[TBL] [Abstract][Full Text] [Related]
36. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
Hendriks LEL; Bootsma G; Mourlanette J; Henon C; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Duchemann B; Cousin S; le Pechoux C; Botticella A; De Ruysscher D; Dingemans AC; Besse B
Eur J Cancer; 2019 Jul; 116():182-189. PubMed ID: 31203193
[TBL] [Abstract][Full Text] [Related]
37. Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas.
Conde-Moreno AJ; García-Gómez R; Albert-Antequera M; Almendros-Blanco P; De Las Peñas-Bataller R; González-Vidal V; López-Torrecilla JL; Ferrer-Albiach C
Rep Pract Oncol Radiother; 2015; 20(3):231-8. PubMed ID: 25949228
[TBL] [Abstract][Full Text] [Related]
38. Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab.
Bergen ES; Binter A; Starzer AM; Heller G; Kiesel B; Tendl-Schulz K; Bago-Horvath Z; Furtner J; Leitner J; Exner R; Fitzal F; Dieckmann K; Widhalm G; Preusser M; Berghoff AS; Bartsch R
Ther Adv Med Oncol; 2021; 13():17588359211009002. PubMed ID: 33995593
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
Ahn MJ; Chiu CH; Cheng Y; Han JY; Goldberg SB; Greystoke A; Crawford J; Zhao Y; Huang X; Johnson M; Vishwanathan K; Yates JWT; Brown AP; Mendoza-Naranjo A; Mok T
J Thorac Oncol; 2020 Apr; 15(4):637-648. PubMed ID: 31887431
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
